Posters/Exhibits/Break > Session
Posters/Exhibits/Break
Presentations
A2. PLATELET ACTIVATION AND BIOCHEMISTRY | |||||
|
(601) IL-6-INDUCED POTENTIATION OF PLATELET ACTIVITY AND GLYCOSYLATION IN VENOUS THROMBOEMBOLISM Michelle K. Brenner1, Karin Hoffmeister2, Brian Branchford1. 1Pediatric Hematology/Oncology/Bone Marrow Transplant, Children’s Wisconsin and Medical College of Wisconsin, Milwaukee, WI, USA 2Translational Glycomics Center, Versiti Blood Research Institute, Milwaukee, WI, USA |
||||
A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION | |||||
|
(602) PLATELET-NUCLEIC ACID RECEPTOR PROMOTES PULMONARY THROMBO-INFLAMMATION IN SICKLE CELL DISEASE Rikesh K. Dubey1, Omika Katoch1, Prithu Sundd1,2. 1Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI, USA 2Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA |
||||
A4. DISORDERS OF PLATELET NUMBER OR FUNCTION | |||||
|
(603) ATHN TRANSCENDS: NATURAL HISTORY COHORT STUDY OF BLEEDING SYMPTOMS AND TREATMENT OUTCOMES IN PATIENTS WITH GLANZMANN THROMBASTHENIA Divyaswathi Citla Sridhar1, Sanjay Ahuja2, Tammuella Chrisentery-Singleton3, Carrie O'Neil3, Catherine Rea4, Jigar Amin4, Mike Recht5,6, Meera Chitlur7. 1Arkansas Children’s Hospital, University of Arkansas for Medical Sciences, Little Rock, AR, USA 2Rainbow Babies & Children’s Hospital, Case Western Reserve University, Cleveland, OH, USA 3American Thrombosis and Hemostasis Network, Rochester, NY, USA 4Hemab Therapeutics, Cambridge, MA, USA 5National Bleeding Disorders Foundation, New York, NY, USA 6Yale University School of Medicine, New Haven, CT, USA 7Central Michigan University/Children’s Hospital of Michigan, Detroit, MI, USA |
||||
|
(604) ANTI-GPIBα ANTIBODIES IN FNAIT ARE ASSOCIATED WITH RECURRENT MISCARRIAGES Christopher J. Khoury1-3, Pingguo Chen1-4, Guangheng Zhu2,3, Zoya Tawhidi1-3, Alan H. Lazarus1-4,8, Yiming Wang5, Karen Chong6, David Chitayat1,6, Heyu Ni1-4,7,8. 1Department of Laboratory Medicine and Pathobiology, University of Toronto., Toronto, ON, Canada 2Keenan Research Centre for Biomedical Science of St. Michael’s Hospital, Toronto, ON, Canada 3Toronto Platelet Immunology Group, Toronto, ON, Canada 4Canadian Blood Services Centre for Innovation, Toronto, ON, Canada 5Division of Clinical and Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, University of Toronto., Toronto, ON, Canada 6The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada 7Department of Physiology, University of Toronto, Toronto, ON, Canada 8Department of Medicine, University of Toronto, Toronto, ON, Canada |
||||
|
(605) UTILITY OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING (TEG-PM) FOR MONITORING PLATELET TRANSFUSION IN QUALITATIVE PLATELET DISORDERS Robert H. Lee1,2, Tanvi Rudran2, Wolfgang Bergmeier1,2. 1Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA 2UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA |
||||
A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS | |||||
|
(606) TITLE: REAL-WORLD EFFICACY DATA ON ADOLESCENT HEMOPHILIA A PATIENTS TRANSITIONING TO BAY 81-8973 OR BAY 94-9027 IN THE ATHNDATASET Martin Chandler1, Jessica Charlet2, Thomas Moulton2, Michael Recht3,4. 1American Thrombosis & Hemostasis, Rochester, NY, USA 2Bayer Pharmaceuticals, USA, Whippany, NJ, USA 3National Bleeding Disorders Foundation, New York City, NY, USA 4Yale University School of Medicine, New Haven, CT, USA |
||||
A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS | |||||
|
(607) BURDEN OF DISEASE AND IMPACT ON QUALITY OF LIFE IN HEREDITARY FACTOR X DEFICIENCY PATIENTS WHO WERE DIAGNOSED AT BIRTH: FINDINGS FROM THE HEREDITARY FACTOR X DEFICIENCY IN AMERICA SURVEY Kim Clark1, Amy Wu2, Denise A. Garner2, Lorie Mody2, Jaymin Patel2, Brian Branchford3. 1Kedrion Biopharma, INC., Fort Lee, NJ, USA 2AESARA, INC., Chapel Hill, NC, USA 3Versiti Blood Research Institute, Medical College of Wisconsin, and Children's Wisconsin, Milwaukee, WI, USA |
||||
|
(608) REBLEED INCIDENCE WITH EPTACOG BETA TREATMENT THROUGH 24 AND 48 HOURS IN CHILDREN (UNDER 12 YEARS) WITH HEMOPHILIA A OR B WITH INHIBITORS Amy L. Dunn1, Manuel Carcao2, Meera Chitlur3, Joanna Davis4, Nina Hwang5, Craig Kessler6, Catherine McGuinn7, Danielle Nance8, Robert Sidonio Jr.9, Tammuella Chrisentery-Singleton10, Courtney D. Thornburg11,12, Michael Wang13, Steven Pipe14. 1Nationwide Children’s Hospital and The Ohio State University College of Medicine, Columbus, OH, USA 2The Hospital for Sick Children, Toronto, ON, Canada 3Central Michigan University College of Medicine/Children’s Hospital of Michigan, Carmen and Ann Adams Department of Pediatrics, Division of Hematology/Oncology, Detroit, MI, USA 4Pediatric Hemophilia Treatment Center, University of Miami, Miami, FL, USA 5Center for Inherited Blood Disorders, Orange, CA, USA 6Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA 7Department of Pediatrics, Division of Pediatric Hematology/Oncology, Weill Cornell Medicine, New York, NY, USA 8Banner MD Anderson Cancer Center, Gilbert, AZ, USA 9Aflac Cancer and Blood Disorders Center and Emory University, Atlanta, GA, USA 10American Thrombosis and Hemostasis Network, Rochester, NY, USA 11Hemophilia and Thrombosis Treatment Center, Rady Children's Hospital-San Diego, San Diego, CA, USA 12Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, USA 13Hemophilia and Thrombosis Center, University of Colorado, Aurora, CO, USA 14University of Michigan, Ann Arbor, MI, USA |
||||
|
(609) RECURRENT PREGNANCY LOSS IN TYPE 3 VON WILLEBRAND DISEASE WITH A UNIQUE MUTATION PROFILE Amanda D. Kaveney, Claire Philipp. Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA |
||||
|
(610) VALUE OF FUNCTIONAL PROTEIN S ACTIVITY ASSAYS FOR DETECTION OF TYPE II PROTEIN S DEFICIENCY Katharine A. Marsden, Shelbey Bauman, Peter F. Mannion, Morayma Reyes Gil. Cleveland Clinic Foundation, Cleveland, OH, USA |
||||
|
(611) VALIDATING THE JAKPOT PREDICTION RULE FOR IDENTIFYING WHICH PATIENTS WITH ERYTHROCYTOSIS ARE UNLIKELY TO HAVE A JAK2 MUTATION Kevin O'Sullivan1, Roosevelt Lu1, Jason A Freed1, George Goshua2, Justine Ryu2, Rushad Patell1, Barbara D Lam1. 1Beth Israel Deaconess Medical Center, Boston, MA, USA 2Yale Medical Center, New Haven, CT, USA |
||||
|
(612) CLINICAL OUTCOMES IN MILD-MODERATE AND SEVERE PATIENTS WITH HEMOPHILIA B: RESULTS FROM A REAL-WORLD, MULTI-NATIONAL SURVEY Sheena Thakkar1, Lisa Wilcox1, Valeria Merla1, Anna Kane1, Jose Alvir1, Surya Pemmaraju1, Jennifer Mellor2, Ella Morton2, Jade Garratt Wheeldon2, James Pike2, Nathan Ball2, Stevie Olsen2. 1Pfizer Inc, New York, NY, USA 2Adelphi Real World, Bollington, United Kingdom |
||||
|
(613) OUTCOMES IN NORTH AMERICAN PARTICIPANTS WHO RECEIVED EFANESOCTOCOG ALFA PROPHYLAXIS IN THE XTEND-1 STUDY Annette von Drygalski1, Tung Wynn2, Doris Quon3, Anthony KC Chan4, Angela C Weyand5, Davide Matino6, Jennifer Dumont7, Andrew Wilson7, Umer Khan8, Sriya Gunawardena9. 1Division of Hematology/Oncology, Department of Medicine, University of California San Diego, San Diego, CA, USA 2Department of Pediatrics, University of Florida, Gainesville, FL, USA 3Luskin Orthopaedic Institute for Children, Los Angeles, CA, USA 4Department of Pediatrics, McMaster Children’s Hospital, McMaster University, Hamilton, ON, Canada 5Division of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA 6Division of Hematology & Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON, Canada 7Sanofi, Cambridge, MA, USA 8Sanofi, San Diego, CA, USA 9Sanofi, Bridgewater, NJ, USA |
||||
|
(614) HEALTH-RELATED QUALITY OF LIFE AND TREATMENT BURDEN IN PATIENTS WITH HEMOPHILIA A/B WITHOUT INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER8 STUDY Guy Young1, Gary Benson2, Hermann Eichler3, Johnny Mahlangu4, Jesper Skov Neergaard5, Jan Odgaard-Jensen5, Jay Jay Thaung Zaw5, Jameela Sathar6, Huyen Tran7, Tadashi Matsushita8, Emily K. Waters9. 1Hemostasis and Thrombosis Center, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA 2Department of Hematology, Belfast Health and Social Care Trust, Belfast, Ireland 3Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg, Saar, Germany 4Department of Molecular Medicine and Haematology, School of Pathology, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa 5Novo Nordisk A/S, Søborg, Denmark 6Department of Haematology, Ampang Hospital, Selangor, Malaysia 7Ronald Sawers Haemophilia Treatment Centre, Monash University, Melbourne, Australia 8Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan 9Novo Nordisk Inc., Plainsboro, NJ, USA |
||||
A8. ANTITHROMBOTIC THERAPY | |||||
|
(615) ANTICOAGULANT MANAGEMENT OF CANCER-ASSOCIATED THROMBOSIS AND THROMBOCYTOPENIA: A RETROSPECTIVE CHART REVIEW Umaima Abbas1, Ushra Khan1, Robin Mackenzie1, Rija Fatima2, Tzu-Fei Wang3, Caroline Hamm1,4,5, Andrea Cervi1,4,5. 1Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada 2Department of Translational Health Science, University of Windsor, Windsor, ON, Canada 3Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada 4Department of Biomedical Sciences, University of Windsor, Windsor, ON, Canada 5Windsor Regional Hospital, Windsor, ON, Canada |
||||
|
(616) A SURVEY OF CLINICIAN PRACTICE PATTERNS ON THE USE OF INFERIOR VENA CAVA FILTERS FOR VENOUS THROMBOEMBOLISM Jillian Calandra1, Rahman Ladak2, Massimo Sementilli3, Alejandro Lazo-Langner2,4, Deborah Siegal5,6, Tzu-Fei Wang5,6, Rong Luo7, Andrea Cervi7. 1WE-SPARK Health Institute, Windsor, ON, Canada 2Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada 3Department of Biomedical Sciences, University of Windsor, Windsor, ON, Canada 4Lawson Health Research Institute, London, ON, Canada 5Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada 6Ottawa Hospital Research Institute, Ottawa, ON, Canada 7Windsor Regional Hospital, Windsor, ON, Canada |
||||
|
(617) INR ABOVE FIVE WARFARIN EVENTS INPATIENT REQUIRE FOCUS ON PREVENTABLE CASES TO LOWER INCIDENCE Benjamin/J Jung1, Lisa Baumann-Kreuziger1,2, Garret Newkirk1. 1Froedtert and Medical College of Wisconsin, MIlwaukee, WI, USA 2Versiti Blood Center of Wisconsin, Milwaukee, WI, USA |
||||
A9. INFORMATIONAL ABSTRACT (POSTER ONLY) | |||||
|
(618) EVALUATION OF NURSE-MANAGED HEPARIN NOMOGRAM ADHERENCE AFTER IMPLEMENTATION OF AN ELECTRONIC MEDICAL RECORD-EMBEDDED HEPARIN CALCULATOR Taylor Robichaux1, John Lindsley1, Vi Gilmore1, Rosemary Duncan1, Catherine Kiruthi1, Erica Willits2, Michael Streiff3, Rakhi Naik3, Jennifer Yui3, Kathryn Dane1. 1Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, USA 2Department of Nursing, The Johns Hopkins Hospital, Baltimore, MD, USA 3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA |
|||||
|
(619) A COMPARISON OF TARGETED HIGH-RANGE VERSUS LOW-RANGE ANTI-XA GOAL FOR INTRAVENOUS UNFRACTIONATED HEPARIN IN PATIENTS WITH MECHANICAL CIRCULATORY SUPPORT DEVICES Yue Wang, Long To, Mathew Jones, Kristin Griebe. Henry Ford Hospital, Detroit, MI, USA |
|||||